Scarica l'app Stockscreener
74.48
0.15%
-0.11
Dopo l'orario di chiusura:
74.73
0.25
+0.34%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Astrazeneca PLC Borsa (AZN) Ultime notizie
Global Chronic Obstructive Pulmonary Disease Treatment Devices Market to Witness Growth at a CAGR of ~6% by 2032 | DelveInsight - GlobeNewswire Inc.
AstraZeneca’s New Phase III Trial Targets Unresectable Pleural Mesothelioma - TipRanks
AstraZeneca’s Latest Clinical Study: Evaluating AZD5004’s Impact on Drug Interactions - TipRanks
AstraZeneca’s Ongoing Study on Olaparib for Advanced Ovarian Cancer: Market Implications - TipRanks
AstraZeneca’s Promising Phase II Study on AZD6234 for Diabetes Management - TipRanks
AstraZeneca’s Koselugo Study: Real-World Insights from Korea - TipRanks
AstraZeneca’s Andexanet Alfa Study: Real-World Insights and Market Implications - TipRanks
AstraZeneca’s New COPD Study: Potential Market Impacts and Investor Insights - TipRanks
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes - Financial Times
Swedish Stocks in North America – AstraZeneca Rises 0.8 Percent - MarketScreener
Is Now a Good Time to Reenter AstraZeneca PLC Depositary ReceiptMarket Momentum and Signal Alerts Suggest Reversal - beatles.ru
AstraZeneca’s Phase II Study on AZD0901: A Potential Game-Changer in Cancer Treatment - TipRanks
AstraZeneca’s Promising Study on AZD9829 for Blood Cancers: Key Insights for Investors - TipRanks
AstraZeneca’s Olaparib Study: A Potential Game-Changer in Breast Cancer Treatment - TipRanks
AstraZeneca’s New Study on HER2 Expression in Gynecological Cancers: What Investors Need to Know - TipRanks
AstraZeneca’s Tagrisso Mountain Grows, But The Climb Will Be Challenging - insights.citeline.com
What makes AstraZeneca PLC Depositary Receipt stock price move sharplyOutstanding growth strategies - Jammu Links News
Is it the right time to buy AstraZeneca PLC Depositary Receipt stockBreakthrough wealth creation - Jammu Links News
AstraZeneca’s Latest Study on Asthma Inhalers: Key Insights for Investors - TipRanks
What are AstraZeneca PLC Depositary Receipt company’s key revenue driversMassive stock growth - Jammu Links News
How strong is AstraZeneca PLC Depositary Receipt company’s balance sheetGet timely advice on market trends - Jammu Links News
What is the risk reward ratio of investing in AstraZeneca PLC Depositary Receipt stockOutstanding yields - jammulinksnews.com
AstraZeneca’s AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension - The Globe and Mail
Proactive weekly health highlights: AstraZeneca, GSK, hVIVO, Avacta, and more - Proactive financial news
AstraZeneca’s Oral Drug Revolution: Could This Be the Future of Heart & Lung Treatments? - Smartkarma
AstraZeneca Can't Take Diabetes Drug IP Appeal To Top Court - Law360
AstraZeneca reports total voting rights of 1.55 billion ordinary shares - Investing.com
AstraZeneca’s New Study on Endometrial Cancer Treatment: Key Insights for Investors - TipRanks
AstraZeneca’s AZD5004: A New Hope for Obesity and Overweight Management - TipRanks
AstraZeneca’s Ongoing Study on New Breast Cancer Treatment Shows Promise - TipRanks
AstraZeneca’s PRIMROSE Study: A New Frontier in Cancer Treatment - TipRanks
AstraZeneca’s New Heart Failure Study: Potential Market Impact - TipRanks
AstraZeneca’s Promising Study on Advanced Cancer Treatments: A Market Overview - TipRanks
AstraZeneca’s Ongoing Study on Olaparib: Potential Market Implications - The Globe and Mail
AstraZeneca’s LYNPARZA Study: Monitoring Safety in Breast Cancer Treatment - The Globe and Mail
AstraZeneca’s Calquence Study: Ensuring Safety in Real-World Use - The Globe and Mail
AstraZeneca’s New COPD Study: Potential Market Impact - The Globe and Mail
AstraZeneca’s Phase 3b Study on Trastuzumab Deruxtecan: A Potential Game-Changer in Breast Cancer Treatment - The Globe and Mail
AstraZeneca’s Promising Phase III Study in Metastatic Breast Cancer: What Investors Need to Know - TipRanks
AstraZeneca’s Latest Phase IIIB Study: A Potential Game-Changer in Advanced Breast Cancer Treatment - TipRanks
AstraZeneca’s Phase III Study on AZD0780: A Potential Game-Changer in Cardiovascular Health - TipRanks
AstraZeneca’s Latest Study on AZD5004: Implications for Liver Impairment Treatment - TipRanks
AstraZeneca’s Tezepelumab Study: Real-World Impact on Asthma and Cough - TipRanks
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results? - Yahoo Finance
AstraZeneca Announces Updated Share Capital and Voting Rights - TipRanks
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock - Yahoo Finance
AstraZeneca’s GEMINI-NSCLC Study: A New Era in Lung Cancer Research - TipRanks
AstraZeneca’s eVOLVE-Cervical Study: A New Hope for High-Risk Cervical Cancer - TipRanks
AstraZeneca’s PHRASE-HF Study: A Game Changer in Heart Failure Treatment? - TipRanks
AstraZeneca’s Innovative Propellant Study: Market Implications and Future Prospects - TipRanks
AstraZeneca’s COPD Study: New Propellant Shows Promise - TipRanks
AstraZeneca’s GEMINI-PeriOp GC Study: A New Horizon in Cancer Treatment - TipRanks
AstraZeneca PLC (NASDAQ:AZN) Q2 2025 Earnings Call Transcript - Insider Monkey
Why AstraZeneca Stock Was Topping the Market on Tuesday - MSN
AstraZeneca PLC (AZN) Announced Positive Results for its Phase 3 Trial of Gefurulimab - MSN
Accelerating Impact: AstraZeneca and Revna Biosciences Expand Access to Lung Cancer Treatment in Ghana - Yahoo.co
FIVE at FIVE: BAE, Taylor Wimpey, Arkle, Cornish Metal, AstraZeneca - Proactive financial news
AstraZeneca’s Asthma Study Completion: Market Implications and Insights - TipRanks
AstraZeneca’s New Study on Personalized Asthma Treatments in China: Market Implications - TipRanks
Stock Watch: Q2 Earnings Blowouts Resume At AstraZeneca And GSK - insights.citeline.com
AstraZeneca’s Promising Phase IIb Study on AZD3427: Market Implications - TipRanks
AstraZeneca gets clean bill of health from leading investment bank - Proactive Investors
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):